Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors.

Authors :: Nicolini FE
Khoury HJ
Akard L
Rea D
Kantarjian H
Baccarani M
Leonoudakis J
Craig A
Benichou AC
Cortes J
Source :: Haematologica [Haematologica] 2013 Jul; Vol. 98 (7), pp. e78-9. Date of Electronic Publication: 2013 Jun 10.
Publication Year :: 2013

Subjects :: Antineoplastic Agents, Phytogenic pharmacology
Drug Resistance, Neoplasm physiology
Follow-Up Studies
Harringtonines pharmacology
Homoharringtonine
Humans
Leukemia, Myeloid, Accelerated Phase enzymology
Leukemia, Myeloid, Accelerated Phase mortality
Protein Kinase Inhibitors pharmacology
Protein-Tyrosine Kinases metabolism
Survival Rate trends
Antineoplastic Agents, Phytogenic therapeutic use
Drug Resistance, Neoplasm drug effects
Harringtonines therapeutic use
Leukemia, Myeloid, Accelerated Phase drug therapy
Protein Kinase Inhibitors therapeutic use
Protein-Tyrosine Kinases antagonists & inhibitors

Full Text Access

Tools